Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.

Clinical journal of the American Society of Nephrology : CJASN

Volumn 1, Issue 3, 2006, Pages 546-554

  Ruggenenti, Piero ^a   Codreanu, Igor ^a   Cravedi, Paolo ^a   Perna, Annalisa ^a   Gotti, Eliana ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; PILOT STUDY; RABBIT; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PILOT PROJECTS; RABBITS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 33746833139     PISSN: None     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01841105     Document Type: Article

References (0)